World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
115
Citations
45288
World Ranking
4580
National Ranking
2486

Kapil N. Bhalla publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Kapil N. Bhalla sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 611 publications — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Kapil N. Bhalla D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Kapil N. Bhalla sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 115 D-Index — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Kapil N. Bhalla is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with significant contributions to subfields such as Molecular Biology, Hematology, Genetics, Oncology, and Public Health, Environmental and Occupational Health.

The scientist's work addresses several main research topics including:

  • Acute Myeloid Leukemia Research
  • Protein Degradation and Inhibitors
  • Multiple Myeloma Research and Treatments
  • Histone Deacetylase Inhibitors Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chromatin Remodeling and Cancer
  • Chronic Myeloid Leukemia Treatments

Bhalla has published extensively in multiple venues, with frequent contributions to:

  • Blood
  • Cancer Research
  • Blood Cancer Journal
  • JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH
  • Clinical Lymphoma Myeloma & Leukemia

Their recent notable papers include:

  • "Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics" (2020) published in Nature Communications
  • "Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)" (2022) published in Blood Cancer Journal
  • "Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia" (2021) published in Nature Communications
  • "Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia" (2022) published in Journal of Clinical Oncology
  • "Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors" (2020) published in Blood Cancer Discovery

Kapil N. Bhalla has collaborated frequently with several coauthors, including:

  • Courtney D. DiNardo
  • Warren Fiskus
  • Tapan M. Kadia
  • Christopher P. Mill
  • Naval Daver

The accumulated body of work reflects a sustained research focus on acute myeloid leukemia and related hematological malignancies, encompassing mechanistic studies, therapeutic strategies, and clinical trials.

Best Publications

  • Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

    Hagop M Kantarjian;Francis Giles;Lydia Wunderle;Kapil Bhalla

  • Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia.

    Rui Hua Xu;Helene Pelicano;Yan Zhou;Jennifer S. Carew

  • Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 A NOVEL BASIS FOR ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS

    Purva Bali;Michael Pranpat;James Bradner;Maria Balasis

  • Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

    Hagop M. Kantarjian;Francis Giles;Norbert Gattermann;Kapil Bhalla

  • Microtubule-targeted anticancer agents and apoptosis.

    Kapil N Bhalla

  • The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

    Alejandro Villagra;Fengdong Cheng;Hong Wei Wang;Ildelfonso Suarez

  • Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

    Hagop M. Kantarjian;Francis J. Giles;Kapil N. Bhalla;Javier A. Pinilla-Ibarz

  • Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling.

    Siddharth Balachandran;Caryn N. Kim;Wen Chen Yeh;Tak W. Mak

  • Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

    Courtney D. DiNardo;Caitlin R. Rausch;Christopher Benton;Tapan Kadia

  • Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies

    Kapil N. Bhalla

  • Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

    Prince George;Purva Bali;Srinivas Annavarapu;Anna Scuto

  • Bcr-Abl Exerts Its Antiapoptotic Effect Against Diverse Apoptotic Stimuli Through Blockage of Mitochondrial Release of Cytochrome C and Activation of Caspase-3

    Gustavo P. Amarante-Mendes;Caryn Naekyung Kim;Linda Liu;Yue Huang

  • SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress

    Yonghua Yang;Wei Fu;Jiandong Chen;Jiandong Chen;Nancy Olashaw;Nancy Olashaw

  • Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells

    Ramadevi Nimmanapalli;Lianne Fuino;Purva Bali;Maura Gasparetto

  • Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.

    Warren Fiskus;Yongchao Wang;Arun Sreekumar;Kathleen M. Buckley

  • CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs

    Guofu Fang;Caryn Naekyung Kim;Charles L. Perkins;Nimmanapalli Ramadevi

  • Alpha/Beta Interferons Potentiate Virus-Induced Apoptosis through Activation of the FADD/Caspase-8 Death Signaling Pathway

    Siddharth Balachandran;Siddharth Balachandran;P. Christopher Roberts;P. Christopher Roberts;Todd Kipperman;Kapil N. Bhalla

  • Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells.

    Kapil Bhalla;Ana Maria Ibrado;Elena Tourkina;Caroline Tang

  • Targeting HSP90 for cancer therapy

    Devalingam Mahalingam;R. Swords;J. S. Carew;Steffan T Nawrocki

  • A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies

    Francis Giles;Thomas Fischer;Jorge Cortes;Guillermo Garcia-Manero

Frequent Co-Authors

Peter Atadja
Peter Atadja Novartis (Switzerland)
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Francis J. Giles
Francis J. Giles Northwestern University
Jorge E. Cortes
Jorge E. Cortes Augusta University
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Marina Konopleva
Marina Konopleva The University of Texas MD Anderson Cancer Center
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center
Elias Jabbour
Elias Jabbour The University of Texas MD Anderson Cancer Center
Oliver G. Ottmann
Oliver G. Ottmann Cardiff University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative and complementary healthcare careers is a practical step for many students interested in medicine. master's in healthcare administration online programs offer an accessible way to develop leadership and management skills, opening doors to administrative roles in hospitals and clinics.

For those seeking to advance clinical practice, cheapest online bsn to dnp programs can help registered nurses earn a Doctor of Nursing Practice and move into advanced practitioner or educator positions.

If pharmacy interests you, pursuing an online pharmd degree allows flexibility for current professionals or students seeking a pathway to becoming a licensed pharmacist.

Technology is also transforming healthcare. health information technology programs online equip students to manage patient data, support healthcare analytics, and ensure digital security.

Each of these degree options can help you enter or advance in growing healthcare fields, many of which can be pursued online from anywhere in the USA.

Best Scientists Citing Kapil N. Bhalla

Trending Scientists

Recently Published Articles